Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Body mass index (BMI) between 18.0 and 40.0~2. Stable (\>4 weeks prior to the Screening Visit) dose of statin therapy with or without ezetimibe~3. Fasting low-density lipoprotein cholesterol (LDL-C): ≥100 mg/dL for those without cardiovascular disease, or ≥70 mg/dL for those with cardiovascular disease.~4. Fasting triglycerides (TGs) \<400 mg/dL~Key Exclusion Criteria:~1. Women who are pregnant, nursing or breast feeding~2. Currently prescribed a lipid lowering agent other than a statin or ezetimibe.~3. Clinically significant disorder or laboratory abnormality that could contraindicate the administration of study drug, affect compliance, interfere with study evaluations, or confound the interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CIVI 007, Dose A (Type: EXPERIMENTAL): Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
- CIVI 007, Dose B (Type: EXPERIMENTAL): SC injection of PCSK9 inhibitor- dose titration
- CIVI 007, Dose C (Type: EXPERIMENTAL): SC injection of PCSK9 inhibitor- high dose given twice
- Placebo (Type: PLACEBO_COMPARATOR): Placebo SC injection matching PCSK9 inhibitor given twice

Based on this trial design, predict the completion outcome and termination type (if applicable).